Legouffe E, Rodriguez C, Picot M C, Richard B, Klein B, Rossi J F, Commes T
Service d'hematologie-oncologie, Unité de greffe de moelle et d'immunothérapie des cancers, C.H.U. Lapeyronie, Montepellier, France.
Leuk Lymphoma. 1998 Oct;31(3-4):351-7. doi: 10.3109/10428199809059228.
Interleukin-6 plays a central role in normal B-cell maturation and in proliferation of some B-cell malignancies including multiple myeloma and some non Hodgkin's lymphomas (NHL). Furthermore, this cytokine also plays a major role in acute phase response by mediating synthesis of acute phase proteins such as C-reactive protein (CRP). In order to evaluate the exact role of CRP serum level as a simple prognostic factor, we analyzed CRP and IL-6 serum levels in 39 patients with NHL. Eleven patients had low grade NHL, 15 intermediate grade NHL, and 13 high grade NHL. Thirty percent of the patients presented detectable IL-6 serum levels (mean+/-SD: 33.6+/-95.2 U/ml, range: 0 to 500). Increased serum CRP levels were found in 42% of the patients with a mean of 29.2+/-41.97 mg/l] (range: 0 to 129). Thirty seven patients were studied for both markers. Three groups of patients were determined. One with low IL-6 and CRP serum levels (N=21), a second with high level of both markers (N=10), and the third with high serum CRP levels alone (N = 5). Only one patient had high level of serum IL-6 with no detectable CRP. The correlation of serum IL-6 and CRP levels with patient survival was investigated. Median survival in the group with low IL-6 level was not reached. 67% of patients of this group were still alive at 32 months from diagnosis. The group of patients with detectable IL-6 had a median of survival of 12 months (p<0.025). The survival of patients with a CRP<10 mg/l was not reached. 75% of patients survive at 32 months from diagnosis, whereas the group with higher CRP level reached a median survival at 8.5 months (p<0.009). As expected, on univariate analysis, there is a significant relationship between CRP and IL-6 levels (p<0.00017), and CRP levels and B symptoms (p<0.001). Furthermore there is a significant relationship between CRP and LDH levels (p<0.042).These results indicated that CRP may be considered as a valuable and easy prognostic biomarker of NHL.
白细胞介素 -6 在正常 B 细胞成熟以及某些 B 细胞恶性肿瘤（包括多发性骨髓瘤和一些非霍奇金淋巴瘤（NHL））的增殖过程中发挥核心作用。此外，这种细胞因子还通过介导 C 反应蛋白（CRP）等急性期蛋白的合成，在急性期反应中起主要作用。为了评估 CRP 血清水平作为一个简单预后因素的确切作用，我们分析了 39 例 NHL 患者的 CRP 和 IL -6 血清水平。11 例患者为低级别 NHL，15 例为中级别 NHL，13 例为高级别 NHL。30%的患者呈现可检测到的 IL -6 血清水平（均值±标准差：33.6±95.2 U/ml，范围：0 至 500）。42%的患者血清 CRP 水平升高，均值为 29.2±41.97 mg/l（范围：0 至 129）。对 37 例患者的两种标志物进行了研究。确定了三组患者。一组患者的 IL -6 和 CRP 血清水平较低（N = 21），第二组患者两种标志物水平均较高（N = 10），第三组患者仅血清 CRP 水平较高（N = 5）。只有 1 例患者血清 IL -6 水平高而 CRP 检测不到。研究了血清 IL -6 和 CRP 水平与患者生存率的相关性。IL -6 水平低的组未达到中位生存期。该组 67%的患者在诊断后 32 个月时仍存活。可检测到 IL -6 的患者组中位生存期为 12 个月（p<0.025）。CRP<10 mg/l 的患者未达到中位生存期。75%的患者在诊断后 32 个月时存活，而 CRP 水平较高的组中位生存期为 8.5 个月（p<0.009）。正如预期的那样，单因素分析显示，CRP 和 IL -6 水平之间存在显著关系（p<0.00017），CRP 水平与 B 症状之间存在显著关系（p<0.001）。此外，CRP 和乳酸脱氢酶（LDH）水平之间也存在显著关系（p<0.042）。这些结果表明，CRP 可被视为 NHL 一种有价值且易于检测的预后生物标志物。
